News Releases

Rubicon Genomics to Present Data on New ThruPLEX® Enrichment Kit at AMP 2016 Annual Meeting; Also Named 2017 "Company to Watch" Finalist
--Learn More about Rubicon's New ThruPLEX Tag-seq Kit at AMP Corporate Workshop Day and Visit Booth #1475 for information on Rubicon's Portfolio of Library Preparation Products--
--Rubicon Also Reported 70% Year-over-Year Revenue Growth in Third Quarter and Was Selected as Life Science Industry Awards® 2017 Company to Watch Finalist--

ANN ARBOR, Mich., Nov. 7, 2016 /PRNewswire/ -- Rubicon Genomics, Inc. today announced that it will present data on its soon-to-be-launched ThruPLEX® Enrichment Reagent kit at the 2016 Annual Meeting of the Association for Molecular Pathology (AMP), where it is also hosting a Corporate Workshop Day event for its new ThruPLEX® Tag-seq kits. Separately, Rubicon announced that it has been selected as a finalist in the Life Science Industry Awards® "2017 Company to Watch" category. The company also reported that it achieved a 70% increase in revenue in the 3rd quarter of 2016 compared to the prior year period.

At AMP 2016, Rubicon's Dr. Anthony Popkie will present a poster, "ThruPLEX Enrichment Reagent kit: Complete, high-performance library preparation and enrichment tool for NGS on Illumina platforms," on November 12 from 9:45 to 10:45 am. The ThruPLEX Enrichment Reagent kit is used with Agilent SureSelect® baits to enrich gene targets of interest, thereby reducing the amount of required sequencing. It can be used with any ThruPLEX library preparation kit but is expected to be especially useful with ThruPLEX Tag-seq, where enrichment is essential for detecting rare alleles.

At the AMP Corporate Workshop Day on November 9 at 11:00 am, Dr. Anthony Popkie and Shawn Quinn of Curio Genomics will describe the newly released ThruPLEX® Tag-seq  and the ultra-fast Curio software in a short presentation. ThruPLEX Tag-seq creates molecularly tagged and sample-indexed libraries for sequencing on Illumina® NGS platforms using cell-free or fragmented double-stranded DNA samples. By removing library and sequencing amplification errors, ThruPLEX Tag-seq enables detection of low-frequency alleles to 0.5% or less, with fewer false positives and greater confidence.

Rubicon personnel will be available to discuss the company's entire portfolio of DNA library preparation products at AMP 2016 Booth #1475.

Rubicon also reported that it has been selected as a finalist in the Life Sciences Industry Awards "2017 Company to Watch" category. The Life Science Industry Awards  allow thousands of scientists to individually vote for their favorite life science supplier companies in multiple product and service categories.

"The Life Science Industry Awards have been called the 'Oscars' for life science product manufacturers, and we are honored that thousands of participating scientists have selected Rubicon as a finalist in the highly competitive 'Company to Watch' category," said James Koziarz, PhD, Chief Executive Officer of Rubicon. "Our selection reflects the excellence of both our existing and new products, including our ThruPLEX Plasma-seq and ThruPLEX Tag-seq kits, which helped drive a 70% increase in year-over-year revenues in the third quarter of this year."

For more information about Rubicon and its products, visit rubicongenomics.com.

About Rubicon Genomics
Rubicon Genomics develops innovative, high quality, nucleic acid library preparation and companion products for research applications that enable easy, reliable, and highly sensitive analysis of samples. Rubicon is committed to teamwork and continuous improvement to provide excellence to our customers, shareholders, and employees. Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit rubicongenomics.com.

Contacts:  

Media

Rubicon Genomics  

Barbara Lindheim              

Jamie Wibbenmeyer, PhD 

BLL Partners, LLC              

Business Development

(212) 584-2276                   

jwibbenmeyer@rubicongenomics.com                                       

blindheim@bllbiopartners.com     

 

SOURCE Rubicon Genomics, Inc.